Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Beatriz Tlatelpa-RomeroLaboratorio Central de Investigación, Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla 72420, Mexico.ORCID 0000-0003-4080-2975
Luis G Vázquez-de-Lara CisnerosLaboratorio de Medicina Experimental, Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla 72420, Mexico.ORCID 0000-0002-8219-2135
Olga CañadasDepartamento de Bioquímica y Biología Molecular, Facultad de Ciencias Biológicas, Universidad Complutense de Madrid, 28040 Madrid, Spain.ORCID 0000-0002-1932-3796
Amaya Blanco-RiveroDepartamento de Bioquímica y Biología Molecular, Facultad de Ciencias Biológicas, Universidad Complutense de Madrid, 28040 Madrid, Spain.ORCID 0000-0002-2954-6205
Barbara OlmedaDepartamento de Bioquímica y Biología Molecular, Facultad de Ciencias Biológicas, Universidad Complutense de Madrid, 28040 Madrid, Spain.
Jesús Pérez-GilDepartamento de Bioquímica y Biología Molecular, Facultad de Ciencias Biológicas, Universidad Complutense de Madrid, 28040 Madrid, Spain.ORCID 0000-0003-3587-7147
Criselda Mendoza-MillaLaboratorio de Transducción de Señales, Unidad de Investigación, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Ciudad de México 14080, Mexico.
José Luis Martinez-VaqueroLaboratorio Central de Investigación, Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla 72420, Mexico.
Yair RomeroLaboratorio de Biopatología Pulmonar de Enfermedades Fibrosantes, Facultad de Ciencias, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico.ORCID 0000-0002-8707-025X
David Atahualpa Contreras-CruzUnidad Multidisciplinaria de Investigación Experimental, Laboratorio de Síntesis Farmacéutica, Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de México, Batalla 5 de Mayo s/n Esquina Fuerte de Loreto, Ejército de Oriente, Iztapalapa 09230, Mexico.ORCID 0000-0002-9765-7097
René de-la-Rosa ParedesHospital General de Puebla "Dr. Eduardo Vázquez Navarro", Puebla 72490, Mexico.
Sinuhé Ruiz-SalgadoÁrea Académica de Ciencias de la Tierra y Materiales, Universidad Autónoma del Estado de Hidalgo, Pachuca 42184, Mexico.
Roberto Berra-RomaniLaboratorio de Fisiología Cardiovascular, Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla 72420, Mexico.ORCID 0000-0003-4884-0925
Alonso Antonio Collantes-GutiérrezHospital Universitario de Puebla, Puebla 72410, Mexico.
María Susana Pérez-FernándezHospital Universitario de Puebla, Puebla 72410, Mexico.
María Guadalupe Hernández-LinaresLaboratorio de Flujo Continuo y Fotoquímica, Centro de Química, Instituto de Ciencias BUAP, Puebla 72570, Mexico.ORCID 0000-0001-9413-4322
Gabriel Guerrero-LunaLaboratorio de Flujo Continuo y Fotoquímica, Centro de Química, Instituto de Ciencias BUAP, Puebla 72570, Mexico.ORCID 0009-0004-0332-3785
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Pulmonary fibrosis (PF) is characterized by excessive collagen deposition and impaired lung function. Pulmonary surfactant may modulate fibroblast activity and offer therapeutic benefits. We developed a natural porcine pulmonary surfactant (NPPS) enriched with 1,2-dipalmitoyl-rac-glycero-3-phosphatidylethanolamine (PE) and evaluated its biophysical and biological properties. Biophysical analysis showed that PE improved surfactant performance by increasing surface pressure and stability. In vitro, NPPS-PE reduced collagen expression and induced apoptosis in normal human lung fibroblasts; in addition, it decreased proliferation in fibroblasts stimulated with TGF-β. In vivo, NPPS-PE improved gas exchange and significantly reduced collagen deposition in bleomycin-treated mice. These findings suggest that NPPS-PE may be a promising therapeutic strategy for fibrosing lung diseases.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Modulation of Pulmonary Fibrosis by Pulmonary Surfactant-Associated Phosphatidylethanolamine In Vitro and In Vivo. · full record | OpenQuestion